Details of a Researcher - MATSUZAKI Juntaro

Papers - MATSUZAKI Juntaro

Division display 61 - 80 of about 260 ／ All the affair displays >>

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer

N Satomi-Tsushita, A Shimomura, J Matsuzaki, Y Yamamoto, J Kawauchi, ...

PloS one 14 (9), e0222024 (PLoS ONE) 14 ( 9 ) e0222024 2019

Research paper (scientific journal), Accepted

© 2019 Satomi-Tsushita et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The identification of biomarkers for predicting the responsiveness to eribulin in patients with metastatic breast cancer pretreated with an anthracycline and a taxane remains an unmet need. Here, we established a serum microRNA (miRNA)-based prediction model for the emergence of new distant metastases after eribulin treatment. Serum samples were collected from metastatic breast cancer patients prior to eribulin treatment and comprehensively evaluated by miRNA microarray. The prediction model for estimating eribulin efficacy was established using the logistic LASSO regression model. Serum samples were collected from 147 patients, of which 52 developed at least one new distant metastasis after eribulin monotherapy and 95 did not develop new distant metastases. A combination of eight serum miRNAs (miR-4483, miR-8089, miR-4755-3p, miR-296-3p, miR-575, miR-4710, miR-5698 and miR-3160-5p) predicted the appearance of new distant metastases with an area under the curve of 0.79, sensitivity of 0.69 and specificity of 0.82. The serum levels of miR-8089 and miR-5698 were significantly associated with overall survival after the initiation of eribulin treatment. The present study provides evidence that serum miRNA profiling may serve as a biomarker for the responsiveness to eribulin and for predicting the development of new distant metastases in metastatic breast cancer.

Access to Document (DOI)

Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma

A Yokoi, J Matsuzaki, Y Yamamoto, K Tate, Y Yoneoka, H Shimizu, ...

Cancer science 110 (12), 3718 (Cancer Science) 110 ( 12 ) 3718 - 3726 2019

Research paper (scientific journal), Lead author, Accepted

© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. Uterine leiomyosarcoma (ULMS) is the major subtype of uterine sarcoma (US) and contributes to uterine cancer deaths. Although preoperative diagnosis of US remains challenging, frequent application of laparoscopic surgery for benign uterine leiomyomas (ULM) requires precise exclusion of US. MicroRNAs are stably present in the bloodstream, and the application of circulating miRNAs as disease biomarkers has been recognized. In the present study, we aimed to identify diagnostic biomarkers for distinguishing US from ULM by focusing on circulating miRNAs. All serum samples were collected preoperatively between 2009 and 2017, and all cases were histopathologically diagnosed. Whole miRNA profiles were obtained using a miRNA microarray. By analyzing expression levels of the miRNAs, candidate miRNAs were selected based on diagnostic performance in discriminating US from ULM, and a diagnostic model was then constructed. A total of 90 serum samples were analyzed, and clustering analyses revealed that the profiles of ULMS were distinct from those of controls. Based on leave-one-out cross-validation, seven miRNAs were selected as biomarker candidates. Based on model construction, the optimal model consisted of two miRNAs (miR-1246 and miR-191-5p), with an area under the receiver operating characteristic curve (AUC) for identifying ULMS of 0.97 (95% confidence interval [CI], 0.91-1.00). In contrast, serum lactate dehydrogenase had an AUC of only 0.64 (95% CI, 0.34-0.94). Seven serum miRNAs with high diagnostic performance for preoperative US screening were detected, and a promising diagnostic model for ULMS was generated.

Access to Document (DOI)

Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs

S Noda-Narita, A Shimomura, Y Tanabe, J Kawauchi, J Matsuzaki, ...

BMJ supportive & palliative care (BMJ Supportive and Palliative Care) 2019

Research paper (scientific journal), Accepted

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. Objectives: MicroRNAs (miRNAs) have recently been reported as useful diagnostic markers in cancer; however, relationships of miRNAs with adverse events during chemotherapy have yet to be fully described. In this study, we examined the relationship between serum miRNA and the risk of peripheral neuropathy (PN), a common and persistent adverse event induced by paclitaxel, in patients with breast cancer. Methods: A total of 84 serum samples from patients with breast cancer, who received paclitaxel as neoadjuvant or adjuvant chemotherapy, were obtained between January 2011 and September 2013 at National Cancer Center Hospital. Samples were divided, 2:1, into a training cohort and a test cohort, respectively; both cohorts included specimens from patients with severe PN (≥grade 2, PN group) and non-severe PN controls (non-PN group). The training cohort was used to identify miRNAs, and combinations thereof, that could predict PN, which then were validated in the test cohort. Results: Eighty-four patients received paclitaxel: 38 and 46 patients in the PN and non-PN groups, respectively. We identified 15 discriminatory miRNAs with |fold change|>0.5, and 14 combinations of three miRNAs showed the ability to discriminate, with sensitivity, specificity and accuracy of >50%. The most discriminatory miRNA, with the highest |fold change|, was miR-451a, which regulates the expression of the drug-transporter protein P-glycoprotein, potentially promoting paclitaxel resistance. Conclusion: MiR-451a could be a predictive marker for PN caused by paclitaxel-containing chemotherapy; however, further investigation of the underlying mechanism is required to determine the role of miR-451a.

Access to Document (DOI)

Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer

F Urabe, J Matsuzaki, Y Yamamoto, T Kimura, T Hara, M Ichikawa, ...

Clinical Cancer Research 25 (10), 3016-3025 (Clinical Cancer Research) 25 ( 10 ) 3016 - 3025 2019

Research paper (scientific journal), Lead author, Accepted

© 2019 American Association for Cancer Research. Purpose: The high false-positive rate of prostate-specific antigen (PSA) may lead to unnecessary prostate biopsies. Therefore, the United States Preventive Services Task Force recommends that decisions regarding PSA-based screening of prostate cancer should be made with caution in men ages 55–69 years, and that men 70 years should not undergo PSA screening. Here, we investigated the potential of serum miRNAs as an accurate diagnostic method in patients with suspected prostate cancer. Experimental Design: Serum samples of 809 patients with prostate cancer, 241 negative prostate biopsies, and 500 patients with other cancer types were obtained from the National Cancer Center, Japan. Forty-one healthy control samples were obtained from two other hospitals in Japan. Comprehensive microarray analysis was performed for all samples. Samples were divided into three sets. Candidate miRNAs for prostate cancer detection were identified in the discovery set (n ¼ 123). A diagnostic model was constructed using combinations of candidate miRNAs in the training set (n ¼ 484). The performance of the diagnostic model was evaluated in the validation set (n ¼ 484). Results: In the discovery set, 18 candidate miRNAs were identified. A robust diagnostic model was constructed using the combination of two miRNAs (miR-17-3p and miR-1185-2-3p) in the training set. High diagnostic performance with a sensitivity of 90% and a specificity of 90% was achieved in the validation set regardless of the Gleason score and clinical tumor–node–metastasis stage. Conclusions: The model developed in this study may help improve the diagnosis of prostate cancer and reduce the number of unnecessary prostate biopsies.

Access to Document (DOI)

Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes

T Katsuda, J Matsuzaki, T Yamaguchi, Y Yamada, M Prieto-Vila, ...

Elife 8, e47313 (eLife) 8 2019

Research paper (scientific journal), Joint Work, Accepted

© Katsuda et al. Hepatocytes are regarded as the only effective cell source for cell transplantation to treat liver diseases; however, their availability is limited due to a donor shortage. Thus, a novel cell source must be developed. We recently reported that mature rodent hepatocytes can be reprogrammed into progenitor-like cells with a repopulative capacity using small molecule inhibitors. Here, we demonstrate that hepatic progenitor cells can be obtained from human infant hepatocytes using the same strategy. These cells, named human chemically induced liver progenitors (hCLiPs), had a significant repopulative capacity in injured mouse livers following transplantation. hCLiPs redifferentiated into mature hepatocytes in vitro upon treatment with hepatic maturation-inducing factors. These redifferentiated cells exhibited cytochrome P450 (CYP) enzymatic activities in response to CYP-inducing molecules and these activities were comparable with those in primary human hepatocytes. These findings will facilitate liver cell transplantation therapy and drug discovery studies.

Access to Document (DOI)

Generation of functional human hepatocytes in vitro: current status and future prospects

T Yamaguchi, J Matsuzaki, T Katsuda, Y Saito, H Saito, T Ochiya

Inflammation and regeneration 39 (1), 1-9 (Inflammation and Regeneration) 39 ( 1 ) 13 2019

Research paper (scientific journal), Accepted

© 2019 The Author(s). Liver and hepatocyte transplantation are the only effective therapies for late-stage liver diseases, in which the liver loses its regenerative capacity. However, there is a shortage of donors. As a potential alternative approach, functional hepatocytes were recently generated from various cell sources. Analysis of drug metabolism in the human liver is important for drug development. Consequently, cells that metabolize drugs similar to human primary hepatocytes are required. This review discusses the current challenges and future perspectives concerning hepatocytes and hepatic progenitor cells that have been reprogrammed from various cell types, focusing on their functions in transplantation models and their ability to metabolize drugs.

Access to Document (DOI)

Cancer stem-cell marker CD44v9-positive cells arise from Helicobacter pylori–infected CAPZA1-overexpressing cells

H Tsugawa, C Kato, H Mori, J Matsuzaki, K Kameyama, H Saya, ...

Cellular and molecular gastroenterology and hepatology 8 (3), 319-334 (Cellular and Molecular Gastroenterology and Hepatology) 8 ( 3 ) 319 - 334 2019

Research paper (scientific journal), Accepted

© 2019 The Authors Background & Aims: CD44 variant 9 (CD44v9)-positive cancer stem-like cells strongly contribute to the development and recurrence of gastric cancer. However, the origin of CD44v9-positive cells is uncertain. Methods: CD44v9, β-catenin, and epithelial splicing regulatory protein 1 signals were assessed by real-time reverse-transcription polymerase chain reaction, immunoblot analysis, or immunofluorescence microscopy. Capping actin protein of muscle Z-line α subunit 1 (CAPZA1) expression was assessed by immunoblot analysis or immunohistochemical analysis of Mongolian gerbils' gastric mucosa or human biopsy specimens. Levels of oxidative stress were assessed by measuring malondialdehyde and protein carbonylation. Histone H3 acetylation levels in the CAPZA1 proximal promoter region were measured by using chromatin immunoprecipitation analysis with an antibody against the acetylated histone H3 in human gastric carcinoma cell line (AGS) cells. Results: CD44v9 is expressed in CAPZA1-overexpressing cells in human gastric cancer tissues. CAPZA1 overexpression enhanced expression of β-catenin, which is a transcription factor for CD44, and epithelial splicing regulatory protein 1, which increases alternative splicing of CD44 to generate CD44v9. CAPZA1-overexpressing cells after cytotoxin-associated gene A accumulation showed CD44v9 expression by inducing nuclear accumulation of β-catenin, concomitant with the enhancement of expression of Sal-like protein 4 and Krüppel-like factor 5, which encode reprogramming factors. Oxidative stress increased the CAPZA1 expression in AGS cells through the enhancement of histone H3 acetylation of CAPZA1 promoter. CAPZA1 expression was increased depending on oxidative stress in H pylori–infected gastric mucosa. Conclusions: CD44v9 expression is evoked from CAPZA1-overexpressing cells after accumulation of cytotoxin-associated gene A. Our findings provide important insights into the mechanisms underlying the development of CD44v9-positive cells.

Access to Document (DOI)

Molecular characterization of the gastric commensal bacteria progressing gastric carcinogenesis in H. pylori-infected gastric mucosa

H TsugaWa, J Matsuzaki, H Mori, M Suematsu, H Suzuki

HELICOBACTER 24 2019

Research paper (international conference proceedings)

P1. 11-10 Serum MicroRNA Biomarkers for Screening of Resectable Lung Cancer

K Asakura, T Kadota, J Matsuzaki, Y Yoshida, K Nakagawa, H Asamura, ...

Journal of Thoracic Oncology 14 (10), S519 2019

Research paper (international conference proceedings)

MP13-09 NOVEL COMBINATION OF CIRCULATING MIRNAS FOR SPECIFIC DETECTION IN PROSTATE CANCER

F Urabe*, J Matsuzaki, Y Yamamoto, T Kimura, T Hara, S Egawa, ...

The Journal of Urology 201 (Supplement 4), e180-e180 2019

Research paper (international conference proceedings)

ACTR-17. DIAGNOSTIC UTILITY OF SERUM microRNA CLASSIFICATION IN DIFFUSE GLIOMA

M Ohno, J Matsuzaki, J Kawauchi, Y Aoki, J Miura, S Takizawa, K Kato, ...

Neuro-Oncology 21 (Suppl 6), vi16 2019

Research paper (international conference proceedings)

Integrated extracellular microRNA profiling for ovarian cancer screening

A Yokoi, J Matsuzaki, Y Yamamoto, Y Yoneoka, K Takahashi, H Shimizu, ...

Nature communications 9 (1), 1-10 (Nature Communications) 9 ( 1 ) 4319 2018.12

Research paper (scientific journal), Joint Work, Lead author, Accepted

© 2018, The Author(s). A major obstacle to improving prognoses in ovarian cancer is the lack of effective screening methods for early detection. Circulating microRNAs (miRNAs) have been recognized as promising biomarkers that could lead to clinical applications. Here, to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors. A diagnostic model based on expression levels of ten miRNAs is constructed in the discovery set. Validation in an independent cohort reveals that the model is very accurate (sensitivity, 0.99; specificity, 1.00), and the diagnostic accuracy is maintained even in early-stage ovarian cancers. Furthermore, we construct two additional models, each using 9–10 serum miRNAs, aimed at discriminating ovarian cancers from the other types of solid tumors or benign ovarian tumors. Our findings provide robust evidence that the serum miRNA profile represents a promising diagnostic biomarker for ovarian cancer.

Access to Document (DOI)

Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk

H Suzuki, J Matsuzaki

Gut 67 (11), 2071-2072 (Gut) 67 ( 11 ) 2071 - 2072 2018.11

Research paper (scientific journal), Last author, Accepted

Access to Document (DOI)

Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression

S Miyoshi, H Tsugawa, J Matsuzaki, K Hirata, H Mori, H Saya, T Kanai, ...

Anticancer research 38 (11), 6163-6170 (Anticancer Research) 38 ( 11 ) 6163 - 6170 2018.11

Research paper (scientific journal), Accepted

© 2018 International Institute of Anticancer Research.All right reserved. Background/Aim: Cancer stem cells (CSCs) play a critical role in resistance to chemotherapy. CD44 is a cell surface marker of CSCs. CD44 variant 9 (CD44v9) interacts with a cystine-glutamate antiporter (xCT) and is an unfavorable predictive factor in gastric cancer. We investigated the impact of CD44v9 expression on 5-fluorouracil (5-FU) resistance and the efficacy of the xCT inhibitor, sulfasalazine (SASP), in improving drug resistance. Materials and Methods: The human gastric cancer cell line MKN28 was transfected with pRc/CMV plasmids encoding human CD44 or CD44v9, which were used for in vitro and in vivo experiments. Results: CD44v9 expression results in 5-FU resistance by increasing intracellular glutathione and suppressing the drug-induced production of reactive oxygen species (ROS). SASP improved the drug sensitivity of CD44v9-expressing cells. Conclusion: Inhibition of xCT improved the clinical efficacy of chemotherapy against gastric cancer. CD44v9 expression can be a novel biomarker to predict resistance against 5-FU in gastric cancer.

Access to Document (DOI)

Gastric cancer: evidence boosts Helicobacter pylori eradication

H Suzuki, J Matsuzaki

Nature Reviews Gastroenterology & Hepatology 15 (8), 458-460 (Nature Reviews Gastroenterology and Hepatology) 15 ( 8 ) 458 - 460 2018.08

Research paper (scientific journal)

Access to Document (DOI)

Extracellular microRNAs and oxidative stress in liver injury: a systematic mini review

J Matsuzaki, T Ochiya

Journal of clinical biochemistry and nutrition, 17-123 (Journal of Clinical Biochemistry and Nutrition) 63 ( 1 ) 6 - 11 2018.07

Research paper (scientific journal), Lead author, Corresponding author, Accepted

© 2018 JCBN. Recent evidence has suggested that extracelluar microRNAs crucial roles in intercellular communications and are promising as minimally invasive biomarkers for various diseases including cancers. Oxidative stress also plays an essential role in homeostasis and disease development. This systematic review aims to clarify the current evidence on the interaction between oxidative stress and extracellular microRNAs. We identified 32 studies that provided information regarding the association between oxidative stress and extracellular microRNAs: 9 focused on the central nervous system, 11 focused on cardiovascular diseases, and 4 focused on liver injury. Endothelial cell-specific miR-126-3p was the most studied extracellular miRNA associated with oxidative stress. In addition, we highlight some reports that describe the mechanisms of how oxidative stress affects extracellular microRNA profiles in liver injury. In liver injury, the levels of miR-122-5p, miR-192-5p, miR-223-3p, and miR-1224-5p were reported to be elevated in the sera. The release of miR-122-5p, miR-192-5p, and miR-1224-5p from hepatocytes may be attributed to oxidative stress. miR-223-3p could be released from neutrophils and suppress oxidative stress in the liver. Elucidation of the mechanisms of the interaction between extracellular microRNAs and oxidative stress would improve our pathophysiological understanding as well as future medical practice.

Access to Document (DOI)

Absence of high-risk stigmata predicts good prognosis even in severely anemic patients with suspected acute upper gastrointestinal bleeding

M Horibe, Y Ogura, J Matsuzaki, T Kaneko, T Yokota, O Okawa, ...

United European gastroenterology journal 6 (5), 684-690 (United European Gastroenterology Journal) 6 ( 5 ) 684 - 690 2018.06

Research paper (scientific journal), Accepted

© 2018, Author(s) 2018. Background: The need for a blood transfusion, defined as hemoglobin < 70 g/L, is the measure for assessing the risk levels in patients with upper gastrointestinal bleeding (UGIB). However, not all patients with a low hemoglobin level have a poor prognosis. Objective: We assessed the clinical predictive factors associated with poor short-term prognosis in patients with a low hemoglobin level. Methods: In this prospective cohort study, all consecutive patients with suspected acute UGIB at Tokyo Metropolitan Tama Medical Center were enrolled between 2008 and 2015. Then, we extracted those who needed a blood transfusion (hemoglobin < 70 g/L) and explored the variables associated with all-cause mortality within 28 days after presentation. Results: Among 1307 patients, 311 needed a blood transfusion and 13 (4.2%) died from all causes. The presence of high-risk stigmata requiring endoscopic treatment (peptic ulcers; Forrest scores Ia, Ib and IIa; varices with current bleeding or signs of recent bleeding; and spurting or gushing bleeding or visible vessel in other diseases), diagnosed by emergency endoscopy, was a unique factor affecting mortality (odds ratio: 8.47, 95% confidence interval: 1.45–160, P = 0.01). Patients without high-risk stigmata neither died from UGIB nor had rebleeding, irrespective of the hemoglobin levels. Conclusions: Patients without high-risk stigmata showed a good prognosis even if they needed a blood transfusion. This result could facilitate triage of patients with suspected acute UGIB who only need a blood transfusion.

Access to Document (DOI)

Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens

Mori H., Suzuki H., Matsuzaki J., Masaoka T., Kanai T.

United European Gastroenterology Journal (United European Gastroenterology Journal) 6 ( 3 ) 391 - 397 2018.04

Research paper (scientific journal), Accepted

© 2017, © Author(s) 2017. Background and aim: Although sitafloxacin (STFX)-containing regimens are effective rescue treatments for Helicobacter pylori infection, prevalence of fluoroquinolone resistance in H. pylori has increased rapidly worldwide. The change in resistance levels and gyrA mutations, a major cause of fluoroquinolone resistance, after unsuccessful STFX-containing treatment has not been investigated. Methods: We conducted a retrospective, non-randomized study to compare the minimum inhibitory concentrations (MICs) of STFX and the location of gyrA mutations in H. pylori before and after unsuccessful eradication with STFX-containing regimens at Keio University Hospital between December 2011 and March 2015. Results: A total of 266 patients treated with STFX-containing regimens for third-line H. pylori eradication were evaluated. Double mutations in gyrA were acquired by 20.8% of strains that exhibited seven-fold increased STFX MICs, compared to pre-treatment MICs. The STFX MICs did not increase, however, when the location of the gyrA mutations did not change after treatment. Double mutations in gyrA developed in 60.0% of the strains in which eradication failed, which exhibited a baseline mutation at position D91, and in 11.1% of strains with baseline mutations at position N87. Conclusion: Acquisition of double mutations in gyrA evoked high-level resistance to STFX in H. pylori after unsuccessful eradication with STFX-containing regimens.

Access to Document (DOI)

Burden of impaired sleep quality on work productivity in functional dyspepsia

J Matsuzaki, H Suzuki, K Togawa, T Yamane, H Mori, T Komori, ...

United European gastroenterology journal 6 (3), 398-406 (United European Gastroenterology Journal) 6 ( 3 ) 398 - 406 2018.04

Research paper (scientific journal), Lead author, Accepted

© 2017, © Author(s) 2017. Background: Impaired sleep quality is common, and can reduce work productivity in patients with functional dyspepsia (FD). Objective: The objective of this article is to evaluate whether there is a direct association between the presence of FD and the severity of impaired sleep quality, and to calculate the economic loss due to the decreased work productivity associated with sleep quality. Methods: In Study 1, using a web-based survey completed by workers with and without FD, we evaluated impaired sleep quality, work and daily productivity, and the severity of reflux and bowel symptoms. In Study 2, the association between the presence of FD and the severity of impaired sleep quality was validated in a hospital-based cohort. Results: In both Study 1 and 2, although impaired sleep quality was more frequent in participants with FD than in those without FD, the independent association between the presence of FD and the severity of impaired sleep quality was not observed after adjustment for the severity of reflux and bowel symptoms. FD participants with impaired sleep quality reported additional economic loss of 53,500 Japanese yen/month. Conclusion: Although the association between impaired sleep quality and FD was indirect, concomitant impaired sleep quality could worsen economic loss.

Access to Document (DOI)

Predicting the risk of peripheral neuropathy by the combination of four serum microRNAs

S Narita, A Shimomura, Y Tanabe, J Kawachi, J Matsuzaki, S Takizawa, ...

Annals of Oncology 29, vii57-vii58 29 vii57 - vii58 2018

Research paper (international conference proceedings)

Access to Document (DOI)

　 Previous page - Next page 　